Literature DB >> 20219875

Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum.

Daniel J Hackett1, Changpin Zhang, Carla Stefanescu, Robert F Pass.   

Abstract

Measurement of antibody to cytomegalovirus (CMV) glycoprotein B (gB) is valuable in the assessment of the antibody response to infection and to gB-containing vaccines. For this purpose, an enzyme-linked immunosorbent assay (ELISA) with a recombinant CMV gB molecule as the antigen was evaluated. Sera from 168 anti-CMV IgG-positive and 100 seronegative subjects were used to evaluate the anti-gB antibody assay. A cutoff optical density (OD) that would distinguish gB antibody-positive from -negative sera was established. Titers of antibody to gB determined by endpoint dilution were compared with those calculated using regression analysis. The run-to-run and interoperator reproducibilities of results were measured. The mean OD + 5 standard deviations from 50 anti-CMV IgG antibody-negative sera (0.2472) was used as the cutoff between anti-gB antibody-positive and -negative results. All sera from 100 anti-CMV IgG-seronegative subjects were negative for antibody to gB. All but 1 of 168 sera from seropositive subjects were positive for antibody to gB. Observed antibody levels based on titration to the endpoint were very similar to results calculated using linear regression. The run-to-run consistency of endpoints was excellent, with 38 runs from one operator and 48 runs from another all giving results within 1 dilution of the mean value for each of three anti-CMV IgG antibody-positive serum pools. The geometric mean titer of antibody to gB for 99 sera from seropositive blood donors was 1/10,937. This ELISA gives accurate and reproducible results for the relative quantity of anti-CMV gB IgG in serum over a wide range of antibody levels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219875      PMCID: PMC2863374          DOI: 10.1128/CVI.00422-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  14 in total

1.  A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.

Authors:  R F Pass; A M Duliegè; S Boppana; R Sekulovich; S Percell; W Britt; R L Burke
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

2.  Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.

Authors:  David I Bernstein; Mark R Schleiss; Klara Berencsi; Eva Gonczol; Michelle Dickey; Phil Khoury; Michel Cadoz; Claude Meric; John Zahradnik; Anne-Marie Duliege; Stanley Plotkin
Journal:  J Infect Dis       Date:  2002-02-06       Impact factor: 5.226

Review 3.  Human cytomegalovirus glycoproteins.

Authors:  W J Britt; M Mach
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

Review 4.  Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection.

Authors:  Robert F Pass; Rae Lyn Burke
Journal:  Semin Pediatr Infect Dis       Date:  2002-07

Review 5.  A recombinant subunit vaccine approach to HCMV vaccine development.

Authors:  R R Spaete
Journal:  Transplant Proc       Date:  1991-06       Impact factor: 1.066

6.  Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.

Authors:  D Navarro; E Lennette; S Tugizov; L Pereira
Journal:  J Med Virol       Date:  1997-08       Impact factor: 2.327

7.  Vaccine prevention of maternal cytomegalovirus infection.

Authors:  Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

8.  Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells.

Authors:  D Navarro; P Paz; S Tugizov; K Topp; J La Vail; L Pereira
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

9.  Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate.

Authors:  T Compton; D M Nowlin; N R Cooper
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

10.  Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity.

Authors:  G S Marshall; G P Rabalais; G G Stout; S L Waldeyer
Journal:  J Infect Dis       Date:  1992-02       Impact factor: 5.226

View more
  7 in total

1.  Genetic markers of immunoglobulin G and immunity to cytomegalovirus in patients with breast cancer.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Sarumathi Mohan; Paul J Nietert; Lindsay Peterson
Journal:  Cell Immunol       Date:  2016-11-02       Impact factor: 4.868

2.  Immunoglobulin genes influence the magnitude of humoral immunity to cytomegalovirus glycoprotein B.

Authors:  Janardan P Pandey; Emily Kistner-Griffin; Faisal F Radwan; Navtej Kaur; Aryan M Namboodiri; Laurel Black; Mary Ann Butler; Tania Carreón; Avima M Ruder
Journal:  J Infect Dis       Date:  2014-06-27       Impact factor: 5.226

3.  Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.

Authors:  Paul D Griffiths; Anna Stanton; Erin McCarrell; Colette Smith; Mohamed Osman; Mark Harber; Andrew Davenport; Gareth Jones; David C Wheeler; James O'Beirne; Douglas Thorburn; David Patch; Claire E Atkinson; Sylvie Pichon; Paul Sweny; Marisa Lanzman; Elizabeth Woodford; Emily Rothwell; Natasha Old; Ruth Kinyanjui; Tanzina Haque; Sowsan Atabani; Suzanne Luck; Steven Prideaux; Richard S B Milne; Vincent C Emery; Andrew K Burroughs
Journal:  Lancet       Date:  2011-04-09       Impact factor: 79.321

4.  Polymorphisms in Toll-like receptor genes influence antibody responses to cytomegalovirus glycoprotein B vaccine.

Authors:  Ravit Arav-Boger; Genevieve L Wojcik; Priya Duggal; Roxann G Ingersoll; Terri Beaty; Robert F Pass; Robert H Yolken
Journal:  BMC Res Notes       Date:  2012-03-13

5.  Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.

Authors:  Ilona Baraniak; Ariane C Gomes; Isabella Sodi; Toby Langstone; Emily Rothwell; Claire Atkinson; Sylvie Pichon; Fabienne Piras-Douce; Paul D Griffiths; Matthew B Reeves
Journal:  EBioMedicine       Date:  2019-11-15       Impact factor: 8.143

6.  A Novel Multiplexed Enzyme-Linked Immunosorbent Assay for the Detection of IgG Seroreactivity to Cytomegalovirus (CMV) UL144.

Authors:  H Miller; P Simpson; M Forman; A Prigan; S Kehl; B Mesich; M Faron; N Ledeboer; R Arav-Boger
Journal:  J Clin Microbiol       Date:  2021-07-19       Impact factor: 5.948

7.  Immunoproteomic analysis of Plasmodium falciparum antigens using sera from patients with clinical history of imported malaria.

Authors:  Rita M Costa; Fátima Nogueira; Karina P de Sousa; Rui Vitorino; Marcelo S Silva
Journal:  Malar J       Date:  2013-03-18       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.